Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. announced its plans to submit a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration (FDA) for tecarfarin. This designation targets pediatric patients with Kawasaki disease who develop coronary artery aneurysms and require chronic oral anticoagulation. If granted and subsequently approved, the company would be eligible for a Priority Review Voucher, which has recently been valued between $180 million and $205 million. Additionally, Cadrenal outlined a dual-track portfolio strategy, focusing on CAD-1005 for global pharmaceutical opportunities and tecarfarin for regional and rare disease markets.

Cadrenal Therapeutics announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin as a treatment for pediatric patients with Kawasaki disease who develop coronary artery aneurysms. If the designation is granted and tecarfarin is approved, Cadrenal would be eligible to receive a Priority Review Voucher, which has recent open-market valuations of approximately $200 million. The company will highlight this initiative and its Phase 3-ready CAD-1005 platform at the upcoming BIO International Convention.

Cadrenal Therapeutics, Inc. announced that Matthew K. Szot mutually agreed to transition from his role as Chief Financial Officer, effective May 28, 2026. Following his departure, CEO Quang X. Pham was appointed as interim Chief Financial Officer and Principal Accounting Officer while the company conducts a search for a permanent replacement. Mr. Szot will receive a severance payment of $365,806 and a fiscal 2026 target cash bonus of $237,903, along with accelerated vesting of all outstanding stock options.

Cadrenal Therapeutics, Inc. announced its participation in the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. The company will host a webcast presentation at 9:30 a.m. ET and conduct virtual one-on-one meetings with investors. Cadrenal Therapeutics is a late-stage biopharmaceutical company developing therapies for immune and thrombotic conditions, with its lead program CAD-1005 for heparin-induced thrombocytopenia holding Orphan Drug and Fast Track designations.

Cadrenal Therapeutics announced that it received official FDA End-of-Phase 2 meeting minutes, providing clear guidance for the pivotal Phase 3 registration trial of CAD-1005 for heparin-induced thrombocytopenia (HIT). The company plans to advance directly to a randomized, blinded, placebo-controlled Phase 3 study involving approximately 120 patients globally, targeting an NDA submission in 2029. Financially, Cadrenal reported a reduced net loss of $2.5 million for Q1 2026, compared to $3.8 million in the prior year, with lower R&D and G&A expenses. The company held $2.3 million in cash and cash equivalents as of March 31, 2026, and secured an additional $2.5 million in financing in April 2026.

Cadrenal Therapeutics reported a net loss of $2.5 million for the first quarter of 2026, an improvement from $3.8 million in the same period last year. The company's cash and cash equivalents stood at $2.3 million as of March 31, 2026, a decrease from $4.0 million at the end of 2025. Management expressed substantial doubt about the company's ability to continue as a going concern due to ongoing operating losses and expected capital needs. To address this, the company plans to raise additional funds through partnering, equity, and debt financings, and generated $1.3 million in net proceeds from its ATM facility during the quarter.

Cadrenal Therapeutics, Inc. announced the successful completion of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for CAD-1005, its investigational 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT). The FDA provided critical guidance on key elements for the Phase 3 pivotal trial, enabling the company to advance directly to a randomized, blinded, placebo-controlled Phase 3 study. This trial will involve approximately 120 patients across up to 50 global clinical centers, with a projected New Drug Application (NDA) submission in 2029.